{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Moss JA"],"funding":["NICHD NIH HHS","NIAID NIH HHS"],"pagination":["5125-35"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC4135875"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["58(9)"],"pubmed_abstract":["Preexposure prophylaxis using oral regimens involving the HIV nucleoside reverse transcriptase inhibitors tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) demonstrated efficacy in three clinical trials. Adherence was determined to be a key parameter for success. Incorporation of the TDF-FTC combination into intravaginal rings (IVRs) for sustained mucosal delivery could increase product adherence and efficacy compared with those of oral and vaginal gel formulations. A novel pod-IVR technology capable of delivering multiple drugs is described; this constitutes the first report of an IVR delivering TDF and FTC, as well as a triple-combination IVR delivering TDF, FTC, and the entry inhibitor maraviroc (MVC). The pharmacokinetics and preliminary local safety of the two combination po"],"journal":["Antimicrobial agents and chemotherapy"],"pubmed_title":["Pharmacokinetics and preliminary safety study of pod-intravaginal rings delivering antiretroviral combinations for HIV prophylaxis in a macaque model."],"pmcid":["PMC4135875"],"funding_grant_id":["R33 AI079791","R44 AI081552","R33AI079791","R43AI098743","R43 HD075636","R44AI081552","R01AI100744","R43HD075636","R01 AI100744"],"pubmed_authors":["Dinh CT","Lopez G","Moss JA","Brooks AA","Smith JM","Srinivasan P","Smith TJ","Baum MM","Butkyavichene I","Martin A"],"additional_accession":[]},"is_claimable":false,"name":"Pharmacokinetics and preliminary safety study of pod-intravaginal rings delivering antiretroviral combinations for HIV prophylaxis in a macaque model.","description":"Preexposure prophylaxis using oral regimens involving the HIV nucleoside reverse transcriptase inhibitors tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) demonstrated efficacy in three clinical trials. Adherence was determined to be a key parameter for success. Incorporation of the TDF-FTC combination into intravaginal rings (IVRs) for sustained mucosal delivery could increase product adherence and efficacy compared with those of oral and vaginal gel formulations. A novel pod-IVR technology capable of delivering multiple drugs is described; this constitutes the first report of an IVR delivering TDF and FTC, as well as a triple-combination IVR delivering TDF, FTC, and the entry inhibitor maraviroc (MVC). The pharmacokinetics and preliminary local safety of the two combination po","dates":{"release":"2014-01-01T00:00:00Z","publication":"2014 Sep","modification":"2025-04-22T00:58:13.713Z","creation":"2019-03-27T01:34:14Z"},"accession":"S-EPMC4135875","cross_references":{"pubmed":["24936594"],"doi":["10.1128/aac.02871-14","10.1128/AAC.02871-14"]}}